ClinicalTrials.gg
RecruitingNCT07456904OnTRACUpdated Jun 18, 2026

Outcomes of Health Care Transition for AYA With a Cancer Predisposition

An observational study in Genetic Predisposition, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
56
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
44th of 50
56 · median 560
Started
2026
with 8 others
Observational
50 of 87
23 open now
Primary completion
2034-11
later than 43 of 45 live
Registered
83rd of 87
by date
Lead sponsor
6 of 87
St. Jude Children's Research Hospital

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 44th largest by planned enrollment of the 50 observational ones that give a count, is one of 9 that started in 2026, is one of 50 observational ones, reaches primary completion later than 43 of the 45 other live ones, and was the 83rd registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

This observational study evaluates whether adolescents and young adults (AYAs) with a cancer predisposition syndrome (CPS) establish and maintain adult health care and continue CPS-specific cancer surveillance after graduating from pediatric care at St. Jude Children's Research Hospital (SJCRH). Participants will complete a Readiness Assessment and periodic surveys over 8 years post-graduation.

Primary Objectives

  • To evaluate whether adolescents and young adults (AYAs) with a cancer predisposition syndrome (CPS) report they have established care with adult health care providers and pursue CPS-specific cancer surveillance within 1-year post-graduation from SJCRH.
  • To evaluate whether AYAs with CPS report they maintain care with adult health care providers and continue CPS-specific cancer surveillance 3 years post-graduation from SJCRH.

Exploratory Objectives:

  • To evaluate whether AYAs with CPS report they continue to maintain care with adult health care providers and complete CPS-specific cancer surveillance longitudinally 5 years and 8 years post-graduation from St. Jude Children's Research Hospital (SJCRH).
  • To examine clinical correlates of establishing care with adult providers and initiating CPS-specific cancer surveillance post-graduation from SJCRH.
  • To identify the tumors diagnosed in AYAs with CPS after they graduate from SJCRH and determine how these tumors were identified (i.e., through specific surveillance tests or based on symptoms).
  • To identify barriers and facilitators AYAs face when establishing and maintaining adult health care and pursuing CPS-specific cancer surveillance.
Read the detailed description

The OnTRAC study investigates the outcomes of AYAs with CPS following their transition from pediatric to adult health care. The study aims to assess whether participants establish care with adult providers and adhere to recommended cancer surveillance protocols. Participants will complete a Readiness Assessment one month post-graduation and electronic Transition Outcomes Surveys at 1, 3, 5, and 8 years. These surveys will evaluate health care engagement, cancer screening adherence, barriers and facilitators to care, and psychosocial experiences. The study will also explore clinical and demographic correlates of successful transition and surveillance adherence.

03

Conditions studied

  • Genetic Predisposition

Keywords

  • Genetic cancer risk
  • Cancer predisposition
  • Health care transition
  • Adolescent and young adult oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants who meet eligibility criteria and consent to enrollment on the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are ≥18 years of age
  • Participants with a molecular or clinical diagnosis of a Cancer Predisposition Syndrome (CPS) who are graduating or have graduated from SJCRH.
  • Participants who were a patient of the SJCRH Cancer Predisposition Clinic for at least 3 years before graduating from SJCRH
  • Participants who require cancer/tumor surveillance within 1 year after graduation from SJCRH. Required cancer/tumor surveillance in adulthood is defined as having a CPS with expert guidelines recommending cancer/tumor surveillance in adulthood
  • Participants fluent in English.

Exclusion criteria

Exclusion Criteria:

  • Participants who are not their own legal medical decision-maker.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
56 participants (estimated)
Patient registry
No

Groups and cohorts

  • Transition Cohort

    AYAs with CPS who have graduated from SJCRH and are followed longitudinally through surveys and assessments to evaluate health care transition outcomes.

    Behavioral: Readiness Assessment · Behavioral: Transition Outcomes Survey A · Behavioral: Transition Outcomes Survey B

Interventions

  • BehavioralReadiness Assessment

    Electronic assessment administered 1 month post-graduation to evaluate transition preparedness.

  • BehavioralTransition Outcomes Survey A

    Administered at 1 and 3 years post-graduation to assess health care engagement and psychosocial outcomes.

  • BehavioralTransition Outcomes Survey B

    Administered at 5 and 8 years post-graduation to assess long-term outcomes and cancer surveillance adherence.

06

What researchers measure

Primary outcomes

  1. Establishment of Adult Health Care

    Proportion of Young Adults with Cancer Predisposition Syndromes Who Have an Identified Adult Medical Provider Managing Cancer Surveillance One Year Post-Pediatric Care Transition

    Time frame: Evaluated 1 year after consent from the study.

  2. Maintenance of Adult Health Care

    Proportion of Young Adults with Cancer Predisposition Syndromes Who Maintain an Identified Adult Medical Provider for Cancer Surveillance Three Years Post-Pediatric Care Transition

    Time frame: Evaluated 3 years after consent from the study.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2034, 101 months after the start.

Of 80 non-industry observational studies under Genetic Predisposition to Disease, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 52. This study's planned 101 months is close to that.

Counting every sponsor, half of 82 studies reached it within 96 months; a quarter within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 9, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Nov 2034
CompletionEst.
Nov 2037
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07456904
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Jun 16, 2026
Primary completion
Nov 2034 (estimated)
Completion
Nov 2037 (estimated)
Last update
Jun 18, 2026

Study contacts

Melissa R Perrino, MD
Contact
referralinfo@stjude.org
888-226-4343
Melissa R Perrino, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion